Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kuti

Showing results (231-240 of 596) with videos related to

Pageof 60
Sort By:
Biomed Research International|August 30, 2021
Prevalence of Intestinal Parasite Infections and Their Associated Factors among Food Handlers Working in Selected Catering Establishments from Bule Hora, EthiopiaSunil Tulshiram Hajare, Robe Kuti Gobena, Nitin Mahendra Chauhan, et al.
Gastroenterology|March 1, 1975
A genetic study of lactose digestion in Nigerian familiesO Ransome-Kuti, N Kretchmer, J D Johnson, et al.
Clinical Therapeutics|August 19, 2007
Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulationKathryn J Eagye, Joseph L Kuti, Michael Dowzicky, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 21, 2004
Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic conceptsSrividya Kotapati, David P Nicolau, Charles H Nightingale, et al.
International Journal of Antimicrobial Agents|December 19, 2008
Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA programPornpan Koomanachai, Jared L Crandon, Joseph L Kuti, et al.
Antimicrobial Agents and Chemotherapy|October 8, 2014
In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureusShawn H MacVane, Wonhee So, David P Nicolau, et al.
Biochimica Et Biophysica Acta|July 16, 2016
Brown adipose tissue in obesity: Fractalkine-receptor dependent immune cell recruitment affects metabolic-related gene expressionÁgnes Polyák, Zsuzsanna Winkler, Dániel Kuti, et al.
Journal of Pharmacy Practice|November 11, 2017
Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal FunctionAbrar K Thabit, Mordechai Grupper, David P Nicolau, et al.
Journal of Managed Care & Specialty Pharmacy|February 28, 2018
Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular DiseaseSandhya Mehta, Sabyasachi Ghosh, Stephen Sander, et al.
Diagnostic Microbiology and Infectious Disease|October 12, 2002
Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysisJoseph L Kuti, Charles H Nightingale, Richard Quintiliani, et al.
Pageof 60

Showing results (231-240 of 596) with videos related to

Sort By:
Pageof 60
Biomed Research International|August 30, 2021
Prevalence of Intestinal Parasite Infections and Their Associated Factors among Food Handlers Working in Selected Catering Establishments from Bule Hora, EthiopiaSunil Tulshiram Hajare, Robe Kuti Gobena, Nitin Mahendra Chauhan, et al.
Gastroenterology|March 1, 1975
A genetic study of lactose digestion in Nigerian familiesO Ransome-Kuti, N Kretchmer, J D Johnson, et al.
Clinical Therapeutics|August 19, 2007
Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulationKathryn J Eagye, Joseph L Kuti, Michael Dowzicky, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 21, 2004
Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic conceptsSrividya Kotapati, David P Nicolau, Charles H Nightingale, et al.
International Journal of Antimicrobial Agents|December 19, 2008
Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA programPornpan Koomanachai, Jared L Crandon, Joseph L Kuti, et al.
Antimicrobial Agents and Chemotherapy|October 8, 2014
In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureusShawn H MacVane, Wonhee So, David P Nicolau, et al.
Biochimica Et Biophysica Acta|July 16, 2016
Brown adipose tissue in obesity: Fractalkine-receptor dependent immune cell recruitment affects metabolic-related gene expressionÁgnes Polyák, Zsuzsanna Winkler, Dániel Kuti, et al.
Journal of Pharmacy Practice|November 11, 2017
Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal FunctionAbrar K Thabit, Mordechai Grupper, David P Nicolau, et al.
Journal of Managed Care & Specialty Pharmacy|February 28, 2018
Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular DiseaseSandhya Mehta, Sabyasachi Ghosh, Stephen Sander, et al.
Diagnostic Microbiology and Infectious Disease|October 12, 2002
Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysisJoseph L Kuti, Charles H Nightingale, Richard Quintiliani, et al.
Pageof 60